title: Angiotensin converting enzyme inhibitor normalizes vascular natriuretic peptide type A receptor gene expression via bradykinin-dependent mechanism in hypertensive rats.
abstract: We previously demonstrated that angiotensin converting enzyme (ACE) inhibitor normalizes the up-regulated gene expression of vascular natriuretic peptide type A (NP-A) receptor in hypertensive rats. To elucidate the mechanism, we examined the effect of angiotensin II receptor (AT1) antagonist (TCV-116) and bradykinin receptor (B2) antagonist (Hoe 140) on the NP-A receptor mRNA level in the aorta of genetically hypertensive rats (SHR-SP/Izm) using ribonuclease protection assay. The effect of ACE inhibitor on the NP-A receptor mRNA level was completely abolished by a concomitant administration of Hoe 140, while TCV-116 did not show any significant effect on the NP-A receptor mRNA level. These results suggest that bradykinin plays an important role in the regulation of the vascular NP-A receptor gene expression.
authors.affiliation: Department of Medicine, Tokyo Women's Medical College, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Yoshimoto
authors.forename: K
authors.initials: K
authors.lastname: Naruse
authors.forename: K
authors.initials: K
authors.lastname: Shionoya
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
authors.forename: T
authors.initials: T
authors.lastname: Seki
authors.forename: H
authors.initials: H
authors.lastname: Hagiwara
authors.forename: S
authors.initials: S
authors.lastname: Hirose
authors.forename: L S
authors.initials: LS
authors.lastname: Kuen
authors.forename: H
authors.initials: H
authors.lastname: Demura
authors.forename: M
authors.initials: M
authors.lastname: Naruse
authors.forename: T
authors.initials: T
authors.lastname: Muraki
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000502:physiology*; D065168:Bradykinin Receptor Antagonists; D015870:Gene Expression / Q000187:drug effects*; D007189:Indans / Q000494:pharmacology*; D051381:Rats; D011918:Rats, Inbred SHR; D043782:Receptor, Bradykinin B2; D017461:Receptors, Atrial Natriuretic Factor / Q000096:biosynthesis*; D013777:Tetrazoles
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D065168:Bradykinin Receptor Antagonists; D007189:Indans; D043782:Receptor, Bradykinin B2; D013777:Tetrazoles; C065679:icatibant; D017461:Receptors, Atrial Natriuretic Factor; C077793:candesartan cilexetil; D001920:Bradykinin; C047759:delapril